Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

83.17 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
The 7 Most Hated Stocks by Institutional Traders ↗
Discover the surprising stocks institutional traders are selling, and find out what their moves could mean for your portfolio's future. 
Via InvestorPlace
News headline image
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope ↗
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,  
Via Benzinga
News headline image
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports ↗
 
Via Benzinga
News headline image
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook ↗
Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key  
Via Benzinga
News headline image
Analyst Expectations for Ionis Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Recap: Ionis Pharmaceuticals Q1 Earnings ↗
 
Via Benzinga
News headline image
Ionis Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
Analyst Expectations for Ionis Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 ↗
 
Via Benzinga
News headline image
Apple To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Monday ↗
Keybanc cut the price target for Baxter International Inc. (NYSE: BAX) from $53 to $51. Keybanc analyst Matthew Mishan maintained an Overweight rating. Baxter International shares rose 1.2% to $47.58... 
Via Benzinga
News headline image
BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease ↗
The companies are working on treatments for a leading cause of heart failure. 
Via Investor's Business Daily
News headline image
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment ↗
Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting  
Via Benzinga
News headline image
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
From Biogen Inc.
Via GlobeNewswire
News headline image
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
News headline image
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million ↗
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A. 
Via Investor's Business Daily
News headline image
Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst ↗
Sunday, Intellia Therapeutics Inc (NASDAQ: NTLA) announced updated interim results from the Phase 1 portion of the ongoing  
Via Benzinga
News headline image
Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway' ↗
Piper Sandler assumed coverage of Ionis Pharmaceuticals Inc (NASDAQ: IONS) with an Overweight rating and a  
Via Benzinga
News headline image
Why Ionis Pharmaceutical Shares Are Trading Lower Wednesday ↗
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading lower on Wednesday after the company announced plans to offer $500 million of senior convertible notes due in 2028 in a private placement... 
Via Benzinga
News headline image
Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79 ↗
The Relative Strength Rating for Ionis Pharmaceuticals stock moved into a new percentile Wednesday, as it got a lift from 65 to 79. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗
 
Via Benzinga
News headline image
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA ↗
The FDA approved Biogen Inc's (NASDAQ: 
Via Benzinga
News headline image
What's Going On With Biogen Stock Tuesday? ↗
Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.  
Via Benzinga
News headline image
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs ↗
 
Via Benzinga
News headline image
3 Biotech Stocks to Sell Before They’re 6 Feet Under ↗
Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid. 
Via InvestorPlace
News headline image
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression ↗
 
Via Benzinga
News headline image
Could This Rare-Disease Drug Candidate Become a Blockbuster? ↗
This drug candidate could be a great treatment option for patients with a potentially deadly disease. 
Via The Motley Fool
News headline image
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward' ↗
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy... 
Via Benzinga
News headline image
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review ↗
 
Via Benzinga
News headline image
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement ↗
The companies are focusing on a small population of ALS patients with a genetic mutation. 
Via Investor's Business Daily
News headline image
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder ↗
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.